Q-omics provides the consensus-scored MIR657 profile across patient tissues and cancer cell-line models. MIR657 expression is associated with patient survival in 17 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, MIR657 is differentially expressed in 9, with the highest sampling consensus in STAD. Additionally, MIR657 RNA expression shows 13,697 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight KIRP, STAD, and TGCT as cancer lineages where MIR657 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR657 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR657 survival associations across molecular data types. MIR657 RNA expression shows survival associations in the most cancer types (17). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR657 RNA expression–survival associations across cancer types. High MIR657 expression shows unfavorable associations in KIRP, HNSC, LUSC, UCEC and CESC, but favorable associations in PAAD. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for MIR657 RNA expression.
This table summarizes MIR657 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR657. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR657 shows lower tumor expression in BRCA, LUSC, KIRP and LUAD and higher tumor expression in STAD and CHOL. The STAD box plot shows higher MIR657 RNA expression in tumor versus normal tissue (log2 FC = +0.466, t-test p = .004).
This table shows molecular features associated with MIR657 in patient tissues and cancer cell lines. In patient samples, MIR657 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
